StockData
Pfizer Inc logo

Pfizer Inc

PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Aug 4, 2026Score 11/3053% above fair value
$30.67+0.15 (+0.49%)

Close on Nov 2, 2026Market cap $174.81BP/E 40.4Yield 5.61%

Pfizer Vyndaqel Family (Vyndaqel / Vyndamax / Vynmac by Quarter

Vyndaqel Family (Vyndaqel / Vyndamax / Vynmac — ATTR-CM) — International revenues ($M) ($M)

QuarterlyAnnual

Pfizer Vyndaqel Family (Vyndaqel / Vyndamax / Vynmac: $698M in Q2 2026, up 11.5% from a year earlier.

Latest, Q2 2026
698
Period ended Jun 28, 2026
Change on a year earlier
+11.5%
626 in Q2 2025
History
33 quarters
Since Q2 2018
Sources
29
Documents cited below

Where the Q2 2026 figure comes from

“|| Vyndaqel family (g) | 1,762 | 1,615 | 9% | 8% | 1,064 | 990 | 7% | 698 | 626 | 12% | 8%”

Source: Form 8-K (Earnings / Guidance Release) (pfe-6282026xex99.htm, filed 2026-08-04) ↗

Reported in Form 8-K Revenue Tables & Form 10-Q / 10-K Segment Footnotes.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedVyndaqel Family (Vyndaqel / Vyndamax / Vynmac — ATTR-CM) — International revenues ($M) ($M)Year on yearSource
Q2 2026Jun 28, 2026698+11.5%Form 8-K (Earnings / Guidance Release) (pfe-6282026xex99.htm, filed 2026-08-04) ↗
Q1 2026Mar 29, 2026691+38.5%Form 8-K (Earnings / Guidance Release) (pfe-3292026xex99.htm, filed 2026-05-05) ↗
Q4 2025Dec 31, 2025778+36.5%Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗
Q3 2025Sep 28, 2025643+32.3%Form 8-K (Earnings / Guidance Release) (pfe-09282025xex99.htm, filed 2025-11-04) ↗
Q2 2025Jun 29, 2025626+35.5%Form 8-K (Earnings / Guidance Release) (pfe-6282026xex99.htm, filed 2026-08-04) ↗
Q1 2025Mar 30, 2025499+29.3%Form 8-K (Earnings / Guidance Release) (pfe-3292026xex99.htm, filed 2026-05-05) ↗
Q4 2024Dec 31, 2024570+33.5%Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗
Q3 2024Sep 29, 2024486+27.6%Form 8-K (Earnings / Guidance Release) (pfe-09282025xex99.htm, filed 2025-11-04) ↗
Q2 2024Jun 30, 2024462+32.8%Form 8-K (Earnings / Guidance Release) (pfe-06292025xex99.htm, filed 2025-08-05) ↗
Q1 2024Mar 31, 2024386+27.8%Form 8-K (Earnings / Guidance Release) (pfe-03302025xex99.htm, filed 2025-04-29) ↗
Q4 2023Dec 31, 2023427+31.0%Form 8-K (Earnings / Guidance Release) (pfe-12312024xex99.htm, filed 2025-02-04) ↗
Q3 2023Oct 1, 2023381+39.6%Form 8-K (Earnings / Guidance Release) (pfe-9292024xex99.htm, filed 2024-10-29) ↗
Q2 2023Jul 2, 2023348+35.9%Form 8-K (Earnings / Guidance Release) (pfe-6302024xex99.htm, filed 2024-07-30) ↗
Q1 2023Apr 2, 2023302-13.0%Form 8-K (Earnings / Guidance Release) (pfe-3312024xex99.htm, filed 2024-05-01) ↗
Q4 2022Dec 31, 2022326+5.2%Form 8-K (Earnings / Guidance Release) (pfe-12312023xex99.htm, filed 2024-01-30) ↗
Q3 2022Oct 2, 20222730.0%Form 8-K (Earnings / Guidance Release) (pfe-10012023xex99.htm, filed 2023-10-31) ↗

Breakdown

What makes up vyndaqel Family (Vyndaqel / Vyndamax / Vynmac

Cite this data

StockData. (2026). Pfizer Vyndaqel Family (Vyndaqel / Vyndamax / Vynmac ($M), quarterly Q2 2018–Q2 2026 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/vyndaqel-intl

See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.